Baxter International Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
4.8
Bearish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
BAX
Consensus analyst target of $22.12 is 29% above current price.
⚠ currently unprofitable (-10% margin).
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
HOLD
Target $22.12 (+28.5%)
13 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
BAX
MRK
—
Trailing P/E
31.5×
8.5×
Forward P/E
11.5×
-9.7%
Profit Margin
13.6%
34.6%
Gross Margin
76.6%
—
ROE
—
2.9%
Revenue Growth
4.9%
—
Earnings Growth
—
0.62
Beta
0.28
—
Price / Book
—
$8.9B
Market Cap
$277.0B
$16 – $33
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →